LV5745B4 - Arstniecibas lidzeklis kas satur tetrahidronaftalina atvasinajumus - Google Patents

Arstniecibas lidzeklis kas satur tetrahidronaftalina atvasinajumus

Info

Publication number: LV5745B4
Authority: LV; Latvia
Prior art keywords: alkyl; dion; benzodiazepine; imidazo; interrupted
Prior art date: 1986-11-14

Application number

LV960155A

Other languages

English (en)

Other versions

LV5745A4 (lv

Inventor

Quirico Branca

Roland Jaeunin

Hans P Maerki

Fraenzi Marti

Henri Ramuz

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-11-14

Filing date

1996-05-24

Publication date

1996-12-20

1996-05-24 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1996-10-20 Publication of LV5745A4 publication Critical patent/LV5745A4/lv

1996-12-20 Publication of LV5745B4 publication Critical patent/LV5745B4/lv

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Heart & Thoracic Surgery (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Cardiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Luminescent Compositions (AREA)
Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Organic Insulating Materials (AREA)
Hydrogenated Pyridines (AREA)
Steroid Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

LV960155A 1986-11-14 1996-05-24 Arstniecibas lidzeklis kas satur tetrahidronaftalina atvasinajumus LV5745B4 (lv)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH456586		1986-11-14
EP87116251A EP0268148B1 (de)	1986-11-14	1987-11-04	Tetrahydronaphthalinderivate und diese enthaltende Arzneimittel

Publications (2)

Publication Number	Publication Date
LV5745A4 LV5745A4 (lv)	1996-10-20
LV5745B4 true LV5745B4 (lv)	1996-12-20

Family

ID=4278454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LV960155A LV5745B4 (lv)	1986-11-14	1996-05-24	Arstniecibas lidzeklis kas satur tetrahidronaftalina atvasinajumus

Country Status (31)

Country	Link
US (1)	US4808605A (lv)
EP (1)	EP0268148B1 (lv)
JP (1)	JP2504490B2 (lv)
KR (1)	KR960004863B1 (lv)
CN (1)	CN1028991C (lv)
AT (1)	ATE70267T1 (lv)
AU (1)	AU600769B2 (lv)
BG (1)	BG60937B2 (lv)
CA (1)	CA1319144C (lv)
CS (2)	CS264350B2 (lv)
DE (2)	DE19775076I2 (lv)
DK (1)	DK171349B1 (lv)
DZ (1)	DZ1142A1 (lv)
ES (1)	ES2040234T3 (lv)
FI (1)	FI94414C (lv)
GR (1)	GR3004029T3 (lv)
HK (1)	HK110494A (lv)
HU (1)	HU215915B (lv)
IE (1)	IE60695B1 (lv)
IL (1)	IL84407A (lv)
LV (1)	LV5745B4 (lv)
MC (1)	MC1883A1 (lv)
MX (1)	MX173614B (lv)
NL (1)	NL970019I2 (lv)
NO (2)	NO172237C (lv)
NZ (1)	NZ222474A (lv)
PH (1)	PH23919A (lv)
PT (1)	PT86130B (lv)
SG (1)	SG114194G (lv)
ZA (1)	ZA878362B (lv)
ZW (1)	ZW20087A1 (lv)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2003283A1 (en) *	1988-12-05	1990-06-05	C. Anne Higley	Imidazoles for the treatment of atherosclerosis
CA2011461A1 (en) *	1989-03-20	1990-09-20	Urs Hengartner	Tetrahydronaphthalene derivatives
NL9001522A (nl) *	1990-07-04	1992-02-03	Schreiner Luchtvaart	Werkwijze voor het vervaardigen van een voorwerp bestaande uit een schuimkern en eventueel een of meer afdeklagen.
TW216770B (lv) *	1991-07-23	1993-12-01	Hoffmann La Roche
US5663166A (en) *	1991-10-18	1997-09-02	Genentech, Inc.	Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5250679A (en) *	1991-10-18	1993-10-05	Genentech, Inc.	Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
BR9509760A (pt) *	1994-11-23	1998-06-30	Neurogen Corp	Composto
ATE215108T1 (de)	1995-06-23	2002-04-15	Univ Delft Tech	Verfahren zur herstellung eines schäumbaren filmes
US5910606A (en) *	1996-01-31	1999-06-08	Hoffmann-La Roche Inc.	Process for making α,β-unsaturated carboxylic acids
US5811556A (en) *	1997-04-30	1998-09-22	Roche Colorado Corporation	Preparation of mibefradil via a naphthalenylacetic acid
US5811557A (en) *	1997-04-30	1998-09-22	Roche Colorado Corporation	Preparation of mibefradil via an acetonitrile anion
US5808088A (en) *	1997-04-30	1998-09-15	Roche Colorado Corporation	Preparation of mibefradil via an acetamide anion
US6897305B2 (en) *	1998-06-08	2005-05-24	Theravance, Inc.	Calcium channel drugs and uses
US7101909B2 (en) *	1998-10-12	2006-09-05	Theravance, Inc.	Calcium channel drugs and uses
AR030676A1 (es) *	1999-07-28	2003-09-03	Ortho Mcneil Pharm Inc	Derivados de aminas y amidas como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de la obesidad y otros trastornos, uso de los mismos para la elaboracion de medicamentos y composiciones farmaceuticas que los comprenden
WO2001062741A1 (en) *	2000-02-25	2001-08-30	South Alabama Medical Science Foundation	Tetrahydronaphtalene derivatives and their use
AU2001235363A1 (en) *	2000-02-25	2001-09-03	Novo-Nordisk A/S	Mibefradil analogues and their use
ES2274854T3 (es) *	2000-05-08	2007-06-01	Pfizer Products Inc.	Resolucion enzimatica de moduladores selectivos del receptor de estrogeno.
FR2827862A1 (fr) *	2001-07-27	2003-01-31	Lipha	Derives imidazolylalkylarylalcanoiques et leurs applications en therapeutique
WO2003031415A1 (en) *	2001-10-10	2003-04-17	Aryx Therapeutics	Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina
KR20030037081A (ko) *	2001-11-02	2003-05-12	한국과학기술연구원	Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법
AU2003250483A1 (en)	2002-08-19	2004-03-11	Pfizer Products Inc.	Combination therapy for hyperproliferative diseases
US20050037063A1 (en) *	2003-07-21	2005-02-17	Bolton Anthony E.	Combined therapies
ES2313079T3 (es) *	2003-07-28	2009-03-01	Janssen Pharmaceutica Nv	Benzimidazol, benzotiazol, benzoxazol y su utilizacion como moduladores de lta4h.
WO2006014930A2 (en) *	2004-07-26	2006-02-09	Cotherix, Inc.	Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
EP2351569B1 (en)	2005-10-26	2012-08-22	Asahi Kasei Pharma Corporation	Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2111863B1 (en)	2005-10-26	2012-03-28	Asahi Kasei Pharma Corporation	Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
US7919506B2 (en)	2006-03-10	2011-04-05	Pfizer Inc.	Dibenzyl amine compounds and derivatives
ES2382009T3 (es)	2006-12-01	2012-06-04	Bristol-Myers Squibb Company	Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
TW200906396A (en) *	2007-02-14	2009-02-16	Janssen Pharmaceutica Nv	LTA4H modulators and uses thereof
BRPI0810399B8 (pt) *	2007-04-27	2021-05-25	Actelion Pharmaceuticals Ltd	composto, composição farmacêutica que o contém e uso do mesmo
PT2336125E (pt) *	2008-04-11	2013-03-18	Janssen Pharmaceutica Nv	Tiazolopiridina-2-iloxi-fenil e tiazolopirazin-2-iloxifenil aminas como moduladores de leucotrieno a4 hidrolase
US20110039905A1 (en)	2008-04-25	2011-02-17	Francis Hubler	Benzimidazole derivatives as calcium channel blockers
JP2012506415A (ja)	2008-10-22	2012-03-15	アクテリオンファーマシューティカルズリミテッド	架橋テトラヒドロナフタレン誘導体
WO2010046729A2 (en) *	2008-10-23	2010-04-29	Actelion Pharmaceuticals Ltd	Tetrahydronaphthalene compounds
EP2451944A4 (en)	2009-07-10	2012-11-28	Harvard College	PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS
US8513434B2 (en)	2010-03-02	2013-08-20	Concert Pharmaceuticals Inc.	Tetrahydronaphthalene derivatives
US8575361B2 (en)	2010-03-02	2013-11-05	Concert Pharmaceuticals Inc.	Tetrahydronaphthalene derivatives
US8883844B2 (en)	2010-09-24	2014-11-11	Nitrogenix Inc.	Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
BR112015026513A2 (pt)	2013-04-17	2017-07-25	Pfizer	derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
WO2016055901A1 (en)	2014-10-08	2016-04-14	Pfizer Inc.	Substituted amide compounds
DK3364993T3 (da)	2015-10-22	2023-01-09	Cavion Inc	Fremgangsmåder til behandling af angelman syndrom
CN110545806A (zh) *	2017-02-15	2019-12-06	卡维昂公司	钙通道抑制剂
MX2019012818A (es)	2017-04-26	2020-07-14	Cavion Inc	Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
CA3115235A1 (en)	2018-10-03	2020-04-09	Cavion, Inc.	Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
FI3911648T3 (fi)	2019-01-18	2025-01-10	Astrazeneca Ab	6'-[[[(1s,3s)-3-[[5-(difluorometoksi)-2-pyrimidinyyli]amino]syklopentyyli]amino][1(2h),3'-bipyridin]-2-oni pcsk9:n estäjänä ja menetelmät sen käyttöön
CN115850119A (zh) *	2022-11-26	2023-03-28	南昌大学	一种2-氯芳香胺类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3914216A (en) *	1962-12-18	1975-10-21	Boehringer Sohn Ingelheim	1-Phenyl-3H-1,4-benzodiazepine-2,5-(1H,4H)-diones
BE793460A (fr) *	1971-12-29	1973-06-28	Boehringer Sohn Ingelheim	Nouvelles 1-aryl-3h,1,4-benzodiazepine-2,5-(1h
NZ213651A (en) *	1984-10-11	1989-07-27	Hoffmann La Roche	Tetrahydronapthalene derivatives and medicaments

1987
- 1987-10-26 CA CA000550190A patent/CA1319144C/en not_active Expired - Fee Related
- 1987-10-26 DK DK559987A patent/DK171349B1/da not_active IP Right Cessation
- 1987-11-03 ZW ZW200/87A patent/ZW20087A1/xx unknown
- 1987-11-03 CS CS877874A patent/CS264350B2/cs not_active IP Right Cessation
- 1987-11-04 DE DE1997175076 patent/DE19775076I2/de active Active
- 1987-11-04 ES ES198787116251T patent/ES2040234T3/es not_active Expired - Lifetime
- 1987-11-04 AT AT87116251T patent/ATE70267T1/de active
- 1987-11-04 EP EP87116251A patent/EP0268148B1/de not_active Expired - Lifetime
- 1987-11-04 DE DE8787116251T patent/DE3775177D1/de not_active Expired - Lifetime
- 1987-11-06 NZ NZ222474A patent/NZ222474A/xx unknown
- 1987-11-06 ZA ZA878362A patent/ZA878362B/xx unknown
- 1987-11-09 IL IL84407A patent/IL84407A/xx unknown
- 1987-11-09 AU AU80909/87A patent/AU600769B2/en not_active Ceased
- 1987-11-10 US US07/119,114 patent/US4808605A/en not_active Expired - Lifetime
- 1987-11-10 JP JP62282287A patent/JP2504490B2/ja not_active Expired - Lifetime
- 1987-11-11 HU HU875011A patent/HU215915B/hu not_active IP Right Cessation
- 1987-11-11 DZ DZ870191A patent/DZ1142A1/fr active
- 1987-11-11 PH PH36056A patent/PH23919A/en unknown
- 1987-11-12 MX MX009271A patent/MX173614B/es unknown
- 1987-11-12 MC MC871928A patent/MC1883A1/fr unknown
- 1987-11-13 IE IE307087A patent/IE60695B1/en not_active IP Right Cessation
- 1987-11-13 PT PT86130A patent/PT86130B/pt not_active IP Right Cessation
- 1987-11-13 NO NO874757A patent/NO172237C/no not_active IP Right Cessation
- 1987-11-13 FI FI875024A patent/FI94414C/fi not_active IP Right Cessation
- 1987-11-13 CN CN87107875A patent/CN1028991C/zh not_active Expired - Fee Related
- 1987-11-13 KR KR87012777A patent/KR960004863B1/ko not_active Expired - Fee Related
1991
- 1991-12-20 CS CS913948A patent/CS394891A3/cs unknown
1992
- 1992-03-11 GR GR920400420T patent/GR3004029T3/el unknown
1994
- 1994-02-14 BG BG098469A patent/BG60937B2/bg unknown
- 1994-08-13 SG SG114194A patent/SG114194G/en unknown
- 1994-10-12 HK HK110494A patent/HK110494A/xx not_active IP Right Cessation
1996
- 1996-05-24 LV LV960155A patent/LV5745B4/lv unknown
1997
- 1997-05-27 NL NL970019C patent/NL970019I2/nl unknown
1998
- 1998-01-09 NO NO1998001C patent/NO1998001I1/no unknown

Also Published As

Publication number	Publication date
MC1883A1 (fr)	1989-01-24
KR960004863B1 (en)	1996-04-16
CS264350B2 (en)	1989-07-12
GR3004029T3 (lv)	1993-03-31
NO1998001I1 (no)	1998-01-09
KR880006163A (ko)	1988-07-21
SG114194G (en)	1994-11-25
NZ222474A (en)	1990-02-26
DK171349B1 (da)	1996-09-16
CS787487A2 (en)	1988-11-15
IL84407A0 (en)	1988-04-29
US4808605A (en)	1989-02-28
MX9271A (es)	1993-09-01
JP2504490B2 (ja)	1996-06-05
FI94414B (fi)	1995-05-31
CN1028991C (zh)	1995-06-21
CN87107875A (zh)	1988-05-25
PT86130B (pt)	1990-11-20
IE873070L (en)	1988-05-14
LV5745A4 (lv)	1996-10-20
PH23919A (en)	1990-01-23
FI875024A0 (fi)	1987-11-13
AU8090987A (en)	1988-05-19
ZA878362B (en)	1988-05-16
NL970019I1 (nl)	1997-08-01
ES2040234T3 (es)	1993-10-16
IL84407A (en)	1991-09-16
NO172237C (no)	1993-06-23
ZW20087A1 (en)	1988-07-20
HU215915B (hu)	1999-03-29
DK559987D0 (da)	1987-10-26
AU600769B2 (en)	1990-08-23
EP0268148B1 (de)	1991-12-11
HK110494A (en)	1994-10-21
IE60695B1 (en)	1994-08-10
NO172237B (no)	1993-03-15
DE3775177D1 (de)	1992-01-23
NO874757L (no)	1988-05-16
JPS63139171A (ja)	1988-06-10
HUT60251A (en)	1992-08-28
ATE70267T1 (de)	1991-12-15
DE19775076I2 (de)	2001-08-09
BG60937B2 (bg)	1996-06-28
CS394891A3 (en)	1992-06-17
NO874757D0 (no)	1987-11-13
DZ1142A1 (fr)	2004-09-13
FI875024A7 (fi)	1988-05-15
FI94414C (fi)	1995-09-11
CA1319144C (en)	1993-06-15
PT86130A (en)	1987-12-01
DK559987A (da)	1988-05-15
MX173614B (es)	1994-03-18
EP0268148A1 (de)	1988-05-25
NL970019I2 (nl)	1997-11-03

Publication	Publication Date	Title
LV5745B4 (lv)	1996-12-20	Arstniecibas lidzeklis kas satur tetrahidronaftalina atvasinajumus
NO900306L (no)	1990-07-24	Fremgangsmaate for fremstilling av nye pyrazolopyridin-forbindelser.
NO168418C (no)	1992-02-19	Analogifremgangsmaate for fremstilling av terapeutisk aktive bicykliske forbindelser
IE780119L (en)	1978-07-20	IMIDAZO(1,2-a) QUINOLINE-2-CARBOXYLIC ACIDS
KR890014112A (ko)	1989-10-21	퀴놀리진 및 퀴놀리지논 유도체의 심장 부정맥 치료용 의약품 제조에 있어서의 용도
NO305655B1 (no)	1999-07-05	Antiarytmiske og kardiobeskyttende substituerte indenoylguanidiner, deres anvendelse for fremstilling av legemidler, samt legemiddel inneholdende disse
IL84096A0 (en)	1988-03-31	Therapeutic agent for the treatment of peptic ulcer disease comprising a purine derivative
FI893570A0 (fi)	1989-07-26	Menetelmä lääkeaineina käyttökelpoisten 1H-imidatso/1,2-b/-pyratsolin johdannaisten valmistamiseksi
US3555044A (en)	1971-01-12	Hexahydro-naphthoquinone semicarbazones
NO863996L (no)	1987-04-10	Nye 2-(2-tienyl)-imidazo(4,5-c)pyridinderivater og salter derav, og fremgangsmaate til fremstilling av derivatene.
JPS57131788A (en)	1982-08-14	1,7-naphthyridine derivative